Increased Risk of MI, Stroke for Patients With Hip Fracture

This article originally appeared here.
Share this content:
Increased Risk of MI, Stroke for Patients With Hip Fracture
Increased Risk of MI, Stroke for Patients With Hip Fracture

THURSDAY, Aug. 24, 2017 (HealthDay News) -- Patients with hip fracture have an increased risk of myocardial infarction (MI) and stroke, according to a study published online Aug. 21 in the Journal of Bone and Mineral Research.

Alma B. Pedersen, M.D., Ph.D., from Aarhus University Hospital in Denmark, and colleagues examined the interaction between hip fracture and comorbidity with respect to risks of MI or stroke using data for 110,563 hip fracture patients and 552,774 individuals from the general population.

The researchers found that the 30-day cumulative incidences of MI were 1.15 and 0.09 percent among patients with hip fracture and the general population, respectively (adjusted hazard ratio [aHR], 12.97; 95 percent confidence interval [CI], 11.56 to 14.55). The 30-day cumulative incidences of stroke were 2.16 and 0.21 percent for patients with hip fracture and the general population (aHR, 9.42; 95 percent CI, 8.71 to 10.19). The aHR for MI was 1.05 (95 percent CI, 0.97 to 1.14) between 31 and 365 days after hip fracture and remained at this level during a maximum follow-up of 20 years. For stroke, the aHR was 1.29 (95 percent CI, 1.22 to 1.35) between 31 and 365 days after hip fracture, remained elevated for 10 years, and then decreased to the level of the general population.

"Our finding underscores the importance of targeting multimorbidity, including prevention and adequate treatment, to improve the prognosis of hip fracture patients," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths